Cabaletta Bio $CABA
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-20
ACTIVE TRIALS5
PHASE 3 / 2-32
RECRUITING5
READOUTS ≤12 MONTHS0
READOUT SLIPPED >6 MO60%
Delay Index: of 5 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +14.0 months). See all sponsors →
Open Cabaletta Bio on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| CABA-201 following preconditioning with fludarabine and cyclophosphamide NCT06154252 |
P2/3 | Recruiting | Idiopathic Inflammatory Myopathy; Dermatomyositis | 74 | 2028-07 |
| DSG3-CAART NCT04422912 |
P1/2 | Recruiting | Pemphigus Vulgaris | 40 | 2029-01 (+29 mo) |
| CABA-201 NCT06328777 |
P2/3 | Recruiting | Systemic Sclerosis; Scleroderma | 37 | 2029-07 |
| CABA-201 NCT06359041 |
P1/2 | Recruiting | Generalized Myasthenia Gravis (gMG) | 24 | 2029-09 (+14 mo) |
| CABA-201 NCT06121297 |
P1/2 | Recruiting | Systemic Lupus Erythematosus; Lupus Nephritis | 28 | 2029-12 (+24 mo) |